IP Verse

Therapeutic Uses Of Pharmaceutical Compositions - EP2482812

The patent EP2482812 was granted to Boehringer Ingelheim on Jan 11, 2023. The application was originally filed on Oct 1, 2010 under application number EP10760351A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2482812

BOEHRINGER INGELHEIM
Application Number
EP10760351A
Filing Date
Oct 1, 2010
Status
Granted And Under Opposition
Dec 9, 2022
Grant Date
Jan 11, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GALENICUMOct 11, 2023GALENICUM HEALTH SLUADMISSIBLE
LUIGIOct 11, 2023TER MEER STEINMEISTER & PARTNERADMISSIBLE
SANDOZOct 11, 2023ELKINGTON AND FIFEADMISSIBLE

Patent Citations (54) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS19990262526
DESCRIPTIONEP0564409
DESCRIPTIONUS3174901
DESCRIPTIONUS5093330
DESCRIPTIONWO02068420
DESCRIPTIONWO2004005281
DESCRIPTIONWO2004018467
DESCRIPTIONWO2004018468
DESCRIPTIONWO2004018469
DESCRIPTIONWO2004041820
DESCRIPTIONWO2004046148
DESCRIPTIONWO2004050658
DESCRIPTIONWO2004111051
DESCRIPTIONWO2005051950
DESCRIPTIONWO2005058901
DESCRIPTIONWO2005063750
DESCRIPTIONWO2005082906
DESCRIPTIONWO2005085246
DESCRIPTIONWO2005097798
DESCRIPTIONWO2005110999
DESCRIPTIONWO2006027204
DESCRIPTIONWO2006029769
DESCRIPTIONWO2006041976
DESCRIPTIONWO2006048427
DESCRIPTIONWO2006068163
DESCRIPTIONWO2007005572
DESCRIPTIONWO2007014886
DESCRIPTIONWO2007071738
DESCRIPTIONWO2007128721
DESCRIPTIONWO2007128724
DESCRIPTIONWO2007128761
DESCRIPTIONWO2008017670
DESCRIPTIONWO2009035969
DESCRIPTIONWO2009121945
DESCRIPTIONWO9835958
EXAMINATIONWO2007078726
EXAMINATIONWO2007128761
EXAMINATIONWO2009121945
OPPOSITIONCA2875706
OPPOSITIONEP2285410
OPPOSITIONUS2003078269
OPPOSITIONUS2004022866
OPPOSITIONUS2004097399
OPPOSITIONUS2007014855
OPPOSITIONUS2008107731
OPPOSITIONWO2004032909
OPPOSITIONWO2007078726
OPPOSITIONWO2007128724
OPPOSITIONWO2007128761
OPPOSITIONWO2008042408
OPPOSITIONWO2008113000
OPPOSITIONWO2008114800
OPPOSITIONWO2009121945
OPPOSITIONWO2011039367

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "5549: Linagliptin", Anonymous, Maryadele J. O'Neil, The Merck index : an encyclopedia of chemicals, drugs, and biologicals, RSC Publ., Royal Soc. of Chemistry, (20130101), pages 1022 - 5549, ISBN 1-84973-670-7, XP055618261
OPPOSITION- Anonymous, "5939: Methabenzthiazuron", Anonymous, Maryadele J.O'Neil, The Merck index : an encyclopedia of chemicals, drugs, and biologicals; 14th edition, John Wiley, (20060101), pages 1025 - 5939, ISBN 0-911910-00-X, XP055618227
OPPOSITION- Anonymous, " BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes", ClinicalTrials.gov; NCT00602472, (20080128), ClinicalTrials.gov; NCT00602472, URL: https://classic.clinicaltrials.gov/ct2/show/NCT00602472, (20240305), XP093138008
OPPOSITION- Anonymous, "Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes", ClinicalTrials.gov; NCT00622284, (20080225), ClinicalTrials.gov; NCT00622284, URL: https://classic.clinicaltrials.gov/ct2/show/NCT00622284, (20240305), XP093137998
OPPOSITION- Anonymous, "Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes", (20090528), pages 1 - 3, Clinical Trials, URL: http://clinicaltrials.gov/archive/NCT00601250/2008_01_25, (20090227), XP002517666
OPPOSITION- ANONYMOUS, "Eucreas. Scientific discussion", (20071001), pages 1 - 27, URL: www.emea.europa.eu/humandocs/PDFs/EPAR/eucreas/H-807-en6.pdf, (20090907), XP002544795
OPPOSITION- Anonymous, "JANUMET - sitagliptin and metformin hydrochloride tablet, film coated JANUMET ™ (sitagliptin/metformin HCl) Tablets", Merck & Co., Inc., (20181030), Merck & Co., Inc., (20240306), XP093138354
OPPOSITION- Anonymous, "Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design", ClinicalTrials.gov; NCT00798161, (20081125), ClinicalTrials.gov; NCT00798161, URL: https://classic.clinicaltrials.gov/ct2/show/NCT00798161, (20240305), XP093138000
OPPOSITION- Anonymous, "Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design NCT00798161", Clinicall Trials, (20090924), pages 1 - 25, XP093138000
OPPOSITION- Anonymous, "Umwandlung von dicyandiamid", Anonymous, Eugen Müller, Methoden der Organischen Chemie, (19520101), pages 215 - 219, XP055618239
OPPOSITION- Anonymous, "Umwandlung von dicyandiamid", Methoden der Organischen Chemie, (19520101), pages 215 - 219, XP055618239
OPPOSITION- Ashok Katdare, Mahesh V. Chaubal, "Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems (passage)", Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems, (20060101), pages 206, 299 - 300, XP055615078
OPPOSITION- Axel Kleemann, Jurgen Engel, Bernhard Kutscher And Dietmar Reichert, "Metformin", Pharmaceutical Substances Syntheses, Patents, Applications 3rd Edition, Stuttgart • New York , Thieme , (19990101), pages 1196 - 1197, XP055822104
OPPOSITION- Boehringer Ingelheim, "Efficacy and Safety of B I1356 vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes", ClinicalTvials.gov History of Changes for Study: NCT00601250, (20090528), XP009553976
OPPOSITION- M. Ashford, "Chapter 21: Bioavailability-physicochemical and dosage from factors", Aulton's Pharmaceutics, 3rd Edition, Churchill Livingstone / Elsevier, (20070101), pages 286 - 289, ISBN 9780443101083, XP009552568
OPPOSITION- Pschyrembel, Willibald; Helmut Hildebrandt, "Passage; Medizinisches Wörterbuch", Pschyrembel, Willibald; Helmut Hildebrandt, PSCHYREMBEL, Medizinisches Wörterbuch (257. Auflage), Hamburg, Nikol Verlagsgesellschaft mbH, (19940101), pages 320 - 321, ISBN 3-933203-04-X, XP009553969
OPPOSITION- Stahl Peter Heinrich; Wermuth Camille G, "Monographs on Acids and Bases. Part II: Bases ; Appendix. Table 5", Stahl Peter Heinrich; Wermuth Camille G, STAHL ET AL. (ED.), Handbook of Pharmaceutical Salts, Weinheim , WILEY-VCH , (20020101), pages 310 - 327, 334-345, ISBN 3-906390-26-8, XP009552730
OPPOSITION- Uhlig-Laske Barbara; Ring Arne; Graefe-Mody Ulrike; Friedrich Christian; Herbach Kirsten; Woerle Hans-Juergen; Dugi Klaus A, "Linagliptin, a Potent and Selective DPP-4 Inhibitor, Is Safe and Efficacious in Patients with Inadequately Controlled Type 2 Diabetes Despite Metformin Therapy", Diabetes, American Diabetes Association, US, US , (20090609), vol. 58, no. Suppl. 1, ISSN 0012-1797, page A143, XP008155413
OPPOSITION- INZUCCHI S.E., "Oral Antihyperglycemic Therapy for Type 2 Diabetes Scientific Review.", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, US , (20020101), vol. 287, no. 3, doi:10.1001/jama.287.3.360, ISSN 0098-7484, pages 360 - 372, XP002990855
OPPOSITION- C. J. Bailey; C. Day, "Fixed‐dose single tablet antidiabetic combinations", Diabetes, GB , (20090119), vol. 11, no. 6, doi:10.1111/j.1463-1326.2008.00993.x, ISSN 1462-8902, pages 527 - 533, XP072205660
OPPOSITION- Thomas Leo; Eckhardt Matthias; Langkopf Elke; Tadayyon Moh; Himmelsbach Frank; Mark Michael, "(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quina zolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors", Journal of pharmacology and experimental therapeutics, American Society for Pharmacology and Experimental Therapeutics, US, US , (20080401), vol. 325, no. 1, doi:10.1124/jpet.107.135723, ISSN 0022-3565, pages 175 - 182, XP009105508
OPPOSITION- Yu Lawrence X.; Wang Jin T.; Hussain Ajaz S., "Evaluation of USP apparatus 3 for dissolution testing of immediate-release products", AAPS PharmSci, Springer New York, New York, New York , (20150710), vol. 4, no. 1, doi:10.1208/ps040101, pages 1 - 5, XP035718583
OPPOSITION- Piatti P M; Monti L D; Valsecchi G; Magni F; Setola E; Marchesi F; Galli-Kienle M; Pozza G; Alberti K G, "Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients.", DIABETES CARE, AMERICAN DIABETES ASSOCIATION, ALEXANDRIA, VA, US, US , (20010501), vol. 24, no. 5, doi:10.2337/diacare.24.5.875, ISSN 0149-5992, pages 875 - 880, XP009117897
OPPOSITION- Piatti P M; Monti L D; Valsecchi G; Magni F; Setola E; Marchesi F; Galli-Kienle M; Pozza G; Alberti K G, "Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients.", Diabetes care, US , (20010501), vol. 24, no. 5, doi:10.2337/diacare.24.5.875, ISSN 0149-5992, pages 875 - 880, XP009117897

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents